Drug Administration System

The European Patent Office has published patent application EP3733243A1 for Takeda Pharmaceutical Company Limited's drug administration system, with publication date March 25, 2026. The patent is classified under IPC codes A61N 7/00, A61B 17/00, A61M 37/00, and A61K 41/00. Inventors are MURATA, Naoyuki and YANAI, Shigeo. The patent designates 33 European states including Germany, France, UK, Italy, Spain, and others.

Systems for Adjusting Blood Flow in a Body Lumen

European Patent Office published application EP3893958A1 for Revamp Medical Ltd., covering systems for adjusting blood flow in a body lumen. The medical device invention classifies under A61M and names inventors Razi, Shohat, Avitov, and Benary. The publication initiates the opposition period for third parties to challenge validity before patent grant.

Pooling Device for Single or Multiple Medical Containers

European Patent Office published Takeda Pharmaceutical's patent application EP3860680A2 for a pooling device designed for single or multiple medical containers. The invention covers devices classified under A61M and A61J related to medical fluid administration and pharmaceutical container systems. Six inventors are credited for the device across designated European member states.

Method and Apparatus for Rectal Anaesthesia

The European Patent Office published patent application EP3758782A1 for a method and apparatus for rectal anaesthesia filed by New Medtek Devices Pty Ltd (Australia). The invention classifies under IPC category A61M 25/02 and designates 35 European and PCT contracting states including all major EU member states. This publication initiates the nine-month period during which third parties may file observations or oppositions before the EPO decides on grant.

Hemopexin Therapeutic Formulation Patent

The European Patent Office published patent EP3664893A1 for CSL Behring AG covering hemopexin therapeutic formulations. The patent classifies under A61P 7/04 (hematological agents) with inventors including Gentinetta, Brinkman, Boerema, An, and Miner. The application designates all major European states including DE, FR, GB, IT, NL, ES, and 23 others.

Telomerase inhibitor treating myelodysplastic syndrome

The European Patent Office published patent application EP3658156A1 for Geron Corporation's telomerase inhibitor compound for use in treating myelodysplastic syndrome. The application covers the pharmaceutical composition (A61K31/7125) and therapeutic use (A61P7/00). The patent is designated for all EU member states and extends to 31 European countries.

Therapeutic Compound Patent - Liverpool School of Tropical Medicine

The European Patent Office published patent application EP3571204A2 for therapeutic heterocyclic compounds developed by Liverpool School of Tropical Medicine, The University of Liverpool, and Eisai R&D Management Co., Ltd. The compounds are classified for anti-infective and anti-parasitic applications (A61P 31/04, A61P 33/00). The patent is designated across all 31 EPO member states.

Methods of Treating Schizophrenia - Sumitomo Pharma

The European Patent Office published patent application EP3582815A1 for methods of treating schizophrenia using therapeutic compounds. Applicant Sumitomo Pharma America, Inc. filed for protection in all designated EPC contracting states including Germany, France, UK, Italy, Spain, and 26 others. The patent covers compounds classified under A61K and C07D chemical classes with potential market exclusivity.

Unilever patents antimicrobial thymol, terpineol composition

The European Patent Office published patent application EP3595621A1 for Unilever Global IP Limited and Unilever IP Holdings B.V. The patent covers an antimicrobial composition combining thymol or terpineol with an antimicrobial lipid. The composition has applications in personal care and healthcare products including hair care, skin treatments, and antiseptics.

AG Rokita Urges Final Four Fans to Watch for Human Trafficking Signs

Indiana Attorney General Todd Rokita issued a public awareness announcement urging NCAA Final Four fans in Indianapolis to watch for signs of human trafficking during the April 2026 event. The AG specifically highlighted that medical professionals, restaurant workers, hotel staff, and truck drivers are likely to encounter trafficking victims. This is an informational outreach effort, not a regulatory requirement.